REAL-WORLD IMPACT OF OLANZAPINE AND SAMIDORPHAN ON RATES OF RELAPSE AMONG YOUNG ADULTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER
Author(s)
Andrew J. Cutler, MD1, Hemangi Panchmatia, MSc2, Alejandro G. Hughes, MPH3, Michael J. Doane, MA, PhD2, Hara Oyedeji, CRNP, MS4, Rakesh Jain, MD5;
1Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA
1Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA
OBJECTIVES: Combined olanzapine and samidorphan (OLZ/SAM) is approved for the treatment of schizophrenia and bipolar I disorder (BD-I). In real-world studies, OLZ/SAM treatment significantly reduced acute care events, which serve as proxies for relapse, in the 12 months after initiating OLZ/SAM. This analysis examined relapse rates (disease-related acute care events) in a subgroup of young adults, a population vulnerable to relapse.
METHODS: This claims analysis used data from Komodo Healthcare Map (10/18/2020-12/31/2023). Adults aged 18-34 years with schizophrenia or BD-I, ≥1 OLZ/SAM claim, and ≥12 months’ enrollment in medical/pharmacy benefits before and after the index date were eligible. Disease-related inpatient (IP) admissions and emergency department (ED) visits in 12-month baseline and follow-up periods were compared; results are presented as absolute percent changes. All-cause and mental health-related events were evaluated separately.
RESULTS: Overall, 564 patients with schizophrenia and 418 with BD-I were included. For patients with schizophrenia initiating OLZ/SAM, proportions of patients with ≥1 schizophrenia-related IP admission or ED visit decreased significantly by 12.1% and 6.2% between baseline and follow-up, respectively (both P<0.05). For patients with BD-I initiating OLZ/SAM, proportions of patients with ≥1 BD-I-related IP admission or ED visit decreased significantly by 18.7% and 6.7% between baseline and follow-up, respectively (both P<0.05). In both cohorts, reductions in disease-related acute care events were numerically larger than those reported previously for the main study.
CONCLUSIONS: For young adults with schizophrenia or BD-I who are in an earlier stage of their illness, initiating OLZ/SAM may be an effective strategy for reducing relapse.
METHODS: This claims analysis used data from Komodo Healthcare Map (10/18/2020-12/31/2023). Adults aged 18-34 years with schizophrenia or BD-I, ≥1 OLZ/SAM claim, and ≥12 months’ enrollment in medical/pharmacy benefits before and after the index date were eligible. Disease-related inpatient (IP) admissions and emergency department (ED) visits in 12-month baseline and follow-up periods were compared; results are presented as absolute percent changes. All-cause and mental health-related events were evaluated separately.
RESULTS: Overall, 564 patients with schizophrenia and 418 with BD-I were included. For patients with schizophrenia initiating OLZ/SAM, proportions of patients with ≥1 schizophrenia-related IP admission or ED visit decreased significantly by 12.1% and 6.2% between baseline and follow-up, respectively (both P<0.05). For patients with BD-I initiating OLZ/SAM, proportions of patients with ≥1 BD-I-related IP admission or ED visit decreased significantly by 18.7% and 6.7% between baseline and follow-up, respectively (both P<0.05). In both cohorts, reductions in disease-related acute care events were numerically larger than those reported previously for the main study.
CONCLUSIONS: For young adults with schizophrenia or BD-I who are in an earlier stage of their illness, initiating OLZ/SAM may be an effective strategy for reducing relapse.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO95
Topic
Clinical Outcomes